Biomaterial Approaches for Understanding and Overcoming Immunological Barriers to Effective Oral Vaccinations

Frizzell, Hannah; Woodrow, Kim A.

doi:10.1002/adfm.201907170

Cited by 23 publications

(15 citation statements)

References 213 publications

(527 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The distinguished vaccine effects could be attributed to the adjuvant effects of PLGA, which have been well investigated in previous studies. [ 21 ]…”

Section: Resultsmentioning

confidence: 99%

Nanovaccine‐Mediated Cell Selective Delivery of Neoantigens Potentiating Adoptive Dendritic Cell Transfer for Personalized Immunization

Xiao

Wang

Fang

et al. 2021

Adv Funct Materials

View full text Add to dashboard Cite

Neoantigen vaccines and adoptive dendritic cell (DC) transfer are major clinical approaches to initiate personalized immunity in cancer patients. However, the immunization efficacy is largely limited by the in vivo trajectory including neoantigens’ access to resident DCs and DCs’ access to lymph nodes (LNs). Herein, an innovative strategy is proposed to improve personalized immunization through neoantigen‐loaded nanovaccines synergized with adoptive DC transfer. It is found that it enables selective delivery of neoantigens to resident DCs and macrophages by coating cancer cell membranes onto neoantigen‐loaded nanoparticles. In addition, the nanovaccines promote the secretion of chemokine C‐C motif ligand 2 (CCL2), CCL3, and C‐X‐C motif ligand 10 from macrophages, thus potentiating the access of transferred DCs to LNs. This immunization strategy enables coordinated delivery of identified neoantigens and autologous tumor lysate‐derived undefined antigens, leading to initiation of antitumor T cell immunity in a personalized manner. It significantly inhibits tumor growth in prophylactic and established mouse tumor models. The findings provide a new vision for potentiating adoptive cell transfer by nanovaccines, which may open the door to a transformative possibility for improving personalized immunization.

show abstract

“…The distinguished vaccine effects could be attributed to the adjuvant effects of PLGA, which have been well investigated in previous studies. [ 21 ]…”

Section: Resultsmentioning

confidence: 99%

Nanovaccine‐Mediated Cell Selective Delivery of Neoantigens Potentiating Adoptive Dendritic Cell Transfer for Personalized Immunization

Xiao

Wang

Fang

et al. 2021

Adv Funct Materials

View full text Add to dashboard Cite

show abstract

“…We hypothesize that this could be because limited amount of vaccine that successfully travels to the gut-associated lymphoid tissue (GALT) for the generation of an immune response. Oral vaccines have to travel through increased pH in the stomach, while limited absorption and availability for antigen recognition also occur in the gastrointestinal tract ( 72 ). Increases in the dose or the number of doses or changes to the delivery of the vaccine in an encased vehicle are potential methods to increase orally vaccinated immune responses.…”

Section: Discussionmentioning

confidence: 99%

Mucosal Immunization with DTaP Confers Protection against Bordetella pertussis Infection and Cough in Sprague-Dawley Rats

et al. 2021

View full text Add to dashboard Cite

Pertussis is a respiratory disease caused by the Gram-negative pathogen, Bordetella pertussis ( Bp ). The transition from a whole cell pertussis vaccine (wP; DTP) to an acellular pertussis vaccine (aP; DTaP; Tdap) correlates with an increase in pertussis cases, despite widespread vaccine implementation and coverage, and it is now appreciated that the protection provided by aP rapidly wanes. To recapitulate the localized immunity observed from natural infection, mucosal vaccination with aP was explored using the coughing rat model of pertussis. Overall, our goal was to evaluate the route of vaccination in the coughing rat model of pertussis. Immunity induced by both oral gavage (OG) and intranasal (IN) vaccination of aP in Bp challenged rats over a nine-day infection was compared to intramuscular (IM)-wP and IM-aP immunized rats that were used as positive controls. Our data demonstrate that mucosal immunization of aP resulted in production of anti- Bp IgG antibody titers similar to IM-wP and IM-aP vaccinated controls post-challenge. IN-aP also induced anti- Bp IgA antibodies in the nasal cavity. Immunization with IM-wP, IM-aP, IN-aP, and OG-aP immunization protected against Bp induced cough, while OG-aP immunization did not protect against respiratory distress. Mucosal immunization by both IN and OG administration protected against acute inflammation and decreased bacterial burden in the lung compared to mock vaccinated challenge (MVC) rats. The data presented in this study suggests that mucosal vaccination with aP can induce a mucosal immune response and provide protection against Bp challenge. This study highlights the potential benefits and uses of the coughing rat model of pertussis; however, further questions regarding waning immunity still require additional investigation.

show abstract

“…We hypothesize that this could be because limited amount of vaccine that successfully travels to the gut-associated lymphoid tissue (GALT) for the generation of an immune response. Oral vaccines have to travel through increased pH in the stomach while limited absorption and availability for antigen recognition also occur in the gastrointestinal tract (75). Increase in dose, number of doses, or delivering vaccine in an encased vehicle are potential methods to increase orally vaccinated immune responses.…”

Section: Discussionmentioning

confidence: 99%

Mucosal immunization with DTaP confers protection against Bordetella pertussis infection and cough in Sprague-Dawley rats

Hall

Bitzer

DeJong

et al. 2021

Preprint

View full text Add to dashboard Cite

Pertussis is a respiratory disease caused by the Gram-negative pathogen, Bordetella pertussis (Bp). The transition from a whole cell pertussis vaccine (wP; DTP) to an acellular pertussis vaccine (aP; DTaP; Tdap) correlates with an increase in pertussis cases, despite widespread vaccine implementation and coverage, and it is now appreciated that the protection provided by aP rapidly wanes. To recapitulate the localized immunity observed from natural infection, mucosal vaccination with aP was explored using the coughing rat model of pertussis. Immunity induced by both oral gavage (OG) and intranasal (IN) vaccination of aP in Bp challenged rats over a nine-day infection was compared to intramuscular (IM)-wP and IM-aP immunized rats that were used as positive controls as IM immunization is the current route for wP and aP vaccination. Our data demonstrate that both IN and OG immunization of aP resulted in production of anti-Bp IgG antibody titers similar to IM-wP and IM-aP vaccinated controls post-challenge. IN-aP also induced anti-Bp IgA antibodies in the nasal cavity. Immunization with IM-wP, IM-aP, IN-aP, and OG-aP immunization protected against Bp induced cough, while OG-aP immunization did not protect against respiratory distress Mucosal immunization (IN-aP and OG-aP) also protected against acute inflammation and decreased bacterial burden in the lung compared to mock vaccinated challenge (MVC) rats. The data presented in this study suggests that mucosal vaccination with aP can induce a mucosal immune response and provide protection against Bp> challenge.

show abstract

Biomaterial Approaches for Understanding and Overcoming Immunological Barriers to Effective Oral Vaccinations

Cited by 23 publications

References 213 publications

Nanovaccine‐Mediated Cell Selective Delivery of Neoantigens Potentiating Adoptive Dendritic Cell Transfer for Personalized Immunization

Nanovaccine‐Mediated Cell Selective Delivery of Neoantigens Potentiating Adoptive Dendritic Cell Transfer for Personalized Immunization

Mucosal Immunization with DTaP Confers Protection against Bordetella pertussis Infection and Cough in Sprague-Dawley Rats

Mucosal immunization with DTaP confers protection against Bordetella pertussis infection and cough in Sprague-Dawley rats

Contact Info

Product

Resources

About